A method is provided for the treatment of postmenopausal disorders which comprises administering to a woman in single, oral, daily dose form during an uninterrupted consecutive sequence of 90 days. (a) a daily, oral, dose in an uninterrupted consecutive sequence for 69 days starting on the first day of a naturally occurring or synthetic estrogenic compound effective in the prevention of climacteric symptoms; (b) a daily, oral dose in an uninterrupted consecutive sequence from the 70th day to the...

Certain antidepressants have been found to alleviate sleeping disorders associated with less than normal REM sleep.

A method for treating habit disorders in a human patient comprising administering to the patient an antihabitual amount of a pharmaceutically active compound, which results in activation of a brain reward system, e.g., flupenthixol, or esters thereof or pharmaceutically acceptable salts thereof, either alone or in admixture with a physiologically acceptable diluent.

A mammalian 22444 gene and gene products which are predictive of a susceptibility or predisposition to various neuropsychiatric disorders are provided. Methods of predicting an individual's susceptibility to developing or having a neuropsychiatric disorder via detection of these diagnostic markers are also provided. In addition, compositions and methods for identifying compositions for use in the treatment of neuropsychiatric disorders via these genes and gene products are described.

The present invention relates to a method of treatment of sexual dysfunction e.g. female sexual disfunction by administering to a person in need of treatment an effective amount of gepirone as either a short-term or a long-term therapy.

The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

This invention relates to compounds of the Formula (I): ##STR00001## or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

This invention relates to compounds of the Formula (I): ##STR00001## or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-.alpha. or combinations thereof.

This invention relates to compounds of the Formula (I): ##STR00001## or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.